Literature DB >> 8370185

Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon.

A Gabrielli1, C Di Loreto, R Taborro, M Candela, P Sambo, C Nitti, M G Danieli, F DeLustro, J R Dasch, G Danieli.   

Abstract

We have investigated the distribution of TGF beta using antibodies specific for its intracellular and extracellular forms in full-thickness biopsies of patients with SSc, primary Raynaud's phenomenon (PRP), systemic lupus erythematosus (SLE), and from normal subjects. Nine of 11 SSc biopsies demonstrated intracellular TGF beta in endothelial cells while only 6 exhibited extracellular TGF beta. Endothelial cells in skin biopsies of all PRP patients displayed both intracellular and extracellular TGF beta. All other control biopsies were negative. In patients with PRP, some positively staining fibroblasts were found scattered throughout the dermis. Lastly, extracellular TGF beta was localized in the papillary dermis of PRP and SSc biopsies and in all the dermal layers of SLE patients. No significant staining of TGF beta was observed in the endothelial cells, fibroblasts, or in the extracellular matrix of the majority of biopsies from normal subjects. These data suggest that TGF beta may be one of the cytokines involved in the early stages of pathogenesis of SSc, and that endothelial cells in SSc and PRP may be a source and/or a target of TGF beta.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370185     DOI: 10.1006/clin.1993.1136

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  10 in total

1.  MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma.

Authors:  Honglin Zhu; Yisha Li; Shunlin Qu; Hui Luo; Yaou Zhou; Yanping Wang; Hongjun Zhao; Yunhui You; Xianzhong Xiao; Xiaoxia Zuo
Journal:  J Clin Immunol       Date:  2012-02-04       Impact factor: 8.317

Review 2.  T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities.

Authors:  Francesco Del Galdo; Carol M Artlett
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 3.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

4.  Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice.

Authors:  Naotaka Shiota; Eiichi Kakizoe; Keiko Shimoura; Tetsuya Tanaka; Hideki Okunishi
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

5.  Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis.

Authors:  M Hasegawa; S Sato; K Takehara
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

6.  Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension.

Authors:  Azusa Kitao; Yasunori Sato; Seiko Sawada-Kitamura; Kenichi Harada; Motoko Sasaki; Hiroyasu Morikawa; Susumu Shiomi; Masao Honda; Osamu Matsui; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

7.  Regulation of fibroblast procollagen production. Transforming growth factor-beta 1 induces prostaglandin E2 but not procollagen synthesis via a pertussis toxin-sensitive G-protein.

Authors:  R J McAnulty; R C Chambers; G J Laurent
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

8.  A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Authors:  Jennifer L Sargent; Ausra Milano; Swati Bhattacharyya; John Varga; M Kari Connolly; Howard Y Chang; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

9.  Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis.

Authors:  A Crilly; J Hamilton; C J Clark; A Jardine; R Madhok
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

10.  Elucidating the cellular mechanism for E2-induced dermal fibrosis.

Authors:  DeAnna Baker Frost; Alisa Savchenko; Adeyemi Ogunleye; Milton Armstrong; Carol Feghali-Bostwick
Journal:  Arthritis Res Ther       Date:  2021-02-27       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.